Last update 24 Jun 2024

Ipilimumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)
+ [15]
Target
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (25 Mar 2011),
RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Priority Review (AU)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D04603Ipilimumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Unresectable Esophageal Squamous Cell Carcinoma
US
27 May 2022
Esophageal Carcinoma
JP
26 May 2022
Mesothelioma
JP
27 May 2021
Mesothelioma
JP
27 May 2021
Hepatocellular Carcinoma
US
10 Mar 2020
Advanced Renal Cell Carcinoma
EU
13 Jul 2011
Advanced Renal Cell Carcinoma
IS
13 Jul 2011
Advanced Renal Cell Carcinoma
LI
13 Jul 2011
Advanced Renal Cell Carcinoma
NO
13 Jul 2011
Colorectal Cancer
EU
13 Jul 2011
Colorectal Cancer
IS
13 Jul 2011
Colorectal Cancer
LI
13 Jul 2011
Colorectal Cancer
NO
13 Jul 2011
metastatic non-small cell lung cancer
EU
13 Jul 2011
metastatic non-small cell lung cancer
IS
13 Jul 2011
metastatic non-small cell lung cancer
LI
13 Jul 2011
metastatic non-small cell lung cancer
NO
13 Jul 2011
Microsatellite instability-high colorectal cancer
EU
13 Jul 2011
Microsatellite instability-high colorectal cancer
IS
13 Jul 2011
Microsatellite instability-high colorectal cancer
LI
13 Jul 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 3
US
30 Jan 2022
Bladder CancerPhase 3
US
30 Jan 2022
HER2 negative Gastric CancerPhase 3
JP
05 Nov 2021
HER2 negative Gastric CancerPhase 3
KR
05 Nov 2021
HER2 negative Gastric CancerPhase 3
TW
05 Nov 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
US
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
JP
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
AR
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
AU
08 Oct 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Mismatch repair-deficient Colonic Cancer
Neoadjuvant
Deficient DNA Mismatch Repair (dMMR)
115
qhajypwydx(zvmxaewqck) = wbpkpekbfl yyykvyrgyp (arzywnoqbl, 93 - 100)
Positive
05 Jun 2024
Phase 3
668
uykvakpdlz(jbkpeezfka) = uijsdveaka thoogaaabk (qjfiqdpgcq, 18.8 - 29.4)
Positive
02 Jun 2024
uykvakpdlz(jbkpeezfka) = nfncagocqj thoogaaabk (qjfiqdpgcq, 17.5 - 22.5)
Phase 2
Melanoma
LDH | positive BRAF mutation
156
yvjkkxmile(lplkfcvplm) = cfuzlmeelx jemqowwrnp (gzvaxtesri )
Negative
02 Jun 2024
yvjkkxmile(lplkfcvplm) = qnmnsokeuq jemqowwrnp (gzvaxtesri )
Phase 3
Melanoma
Neoadjuvant | Adjuvant
423
Neoadjuvant IPI 80mg + NIVO 240mg
wlajbqnjdu(yroxzipkqf) = yyoarnkdrb xfwjkrbixs (zjaylpykbi, 73.8 - 94.8)
Positive
02 Jun 2024
Adjuvant DAB/TRAM (150mg BID/2mg QD) or Adjuvant NIVO (480mg; q4w)
wlajbqnjdu(yroxzipkqf) = lqurghuehh xfwjkrbixs (zjaylpykbi, 45.1 - 72.6)
Phase 2
135
ohrztphpwm(danghqkqmt): HR = 0.87 (90% CI, 0.67 - 1.12), P-Value = 0.36
Negative
02 Jun 2024
Phase 2
29
oxyqwnphef(atrsarugrs) = ljcyclueqb dlwtastrve (hqeysmabfk, jeudcqpidl - bumfkdzlzp)
-
29 May 2024
Phase 3
970
Nivolumab + Chemotherapy
csbtrktcgs(tmhgxieblk) = gbhvwdqsra zjdwwgbsrs (sngllbioei, 11.1–15.7)
Positive
24 May 2024
csbtrktcgs(tmhgxieblk) = qdakpircmy zjdwwgbsrs (sngllbioei, 11.3–15.5)
Phase 1/2
Locally Advanced Melanoma
First line
PD-L1 Positive | LAG3 Positive
46
jkyfgvgwgv(gmvjqbiztk) = jketekpozj pfwgralccl (qpxvcubedl, 43.2–73.0)
Positive
24 May 2024
Phase 1
Transitional Cell Carcinoma
TMB | PD-L1 | RNA expression of immune-related genes ...
-
ipi 3 + nivo 1 (ipi-high)
qrsdusnnbr(mzkmdrapah) = quomawquao seoedmsgfn (ibwubnfmsn )
Positive
24 May 2024
ipi 1 + nivo 3 (ipi-low)
qrsdusnnbr(mzkmdrapah) = mqbjyxizpr seoedmsgfn (ibwubnfmsn )
Phase 2
9
NA ipi + nivo + low-dose SBRT
cmpwctskub(bzgdqtphrm) = jnzxwbthlx zlmxfajwrc (wchmfvwrzf )
Negative
24 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free